<?xml version="1.0" encoding="UTF-8"?>
<ref id="B26-biology-09-00252">
 <label>26.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Jovanovic</surname>
    <given-names>L.</given-names>
   </name>
   <name>
    <surname>Dailey</surname>
    <given-names>G.</given-names>
    <suffix>III</suffix>
   </name>
   <name>
    <surname>Huang</surname>
    <given-names>W.C.</given-names>
   </name>
   <name>
    <surname>Strange</surname>
    <given-names>P.</given-names>
   </name>
   <name>
    <surname>Goldstein</surname>
    <given-names>B.J.</given-names>
   </name>
  </person-group>
  <article-title>Repaglinide in type 2 diabetes: A 24-week, fixed-dose efficacy and safety study</article-title>
  <source>J. Clin. Pharmacol.</source>
  <year>2000</year>
  <volume>40</volume>
  <fpage>49</fpage>
  <lpage>57</lpage>
  <pub-id pub-id-type="doi">10.1177/00912700022008694</pub-id>
  <pub-id pub-id-type="pmid">10631622</pub-id>
 </element-citation>
</ref>
